Elaine Inman-Williamson
Adult Medicine · Aiken, SCNPI 1225421472
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,053 and has fallen 59.2% since, to $429 in 2024.
Across 85 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$266
- Novartis$123
- AstraZeneca$100
- Abbott$90
- Merck$90
- AbbVie$86
- plus $868 from 20 others
What the payments were for
- Food & beverage$1,60999%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 14 | $266 |
| Novartis | 6 | $123 |
| AstraZeneca | 6 | $100 |
| Abbott | 5 | $90 |
| Merck | 6 | $90 |
| AbbVie | 4 | $86 |
| Amgen | 5 | $83 |
| Novo Nordisk | 4 | $82 |
| Cequr Corporation | 2 | $73 |
| Melinta Therapeutics, LLC | 3 | $68 |
| Insmed, Inc. | 3 | $51 |
| Pfizer | 3 | $48 |
| Bayer | 2 | $47 |
| VBI Vaccine (delaware) Inc. | 2 | $47 |
| Insulet Corporation | 2 | $47 |
| GSK | 3 | $45 |
| Boehringer Ingelheim | 2 | $43 |
| Corcept Therapeutics | 2 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $28 |
| Exact Sciences | 2 | $28 |
| Hydrofera LLC | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
How this compares
Too few adult medicine providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $92,942 |
| TrulicityDulaglutide | 21 | $39,496 |
| MounjaroTirzepatide | 30 | $36,518 |
| EliquisApixaban | 29 | $29,383 |
| FarxigaDapagliflozin Propanediol | 18 | $20,148 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $15,638 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,782 |
| JardianceEmpagliflozin | 12 | $11,697 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $10,346 |
| Levothyroxine Sodium | 202 | $2,094 |
| Rosuvastatin Calcium | 123 | $1,746 |
| Gabapentin | 82 | $1,687 |
| Atorvastatin Calcium | 183 | $1,596 |
| Omeprazole | 99 | $1,573 |
| Losartan Potassium | 104 | $1,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $82 | $92,94276 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $266 | $76,01451 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $100 | $31,92936 claims |
| PfizerEliquis | $48 | $29,38329 claims |
| GSKTrelegy Ellipta | $45 | $15,63819 claims |
| Boehringer IngelheimJardiance | $43 | $11,69712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other adult medicine in Aiken
- Elizabeth SchappellAiken$150
- Alfred MossGaffney$14K
- Katherine PeilSumter$8K
- Melanie MoleEasley$2K
- Jose Morales VazquezMyrtle Beach$2K
- Samai SupanOkatie$713
- Yvette-Marie PellegrinoBeaufort$635
- Kelly PassarelloSummerville$482
- Kelley MoodyHartsville$290
- Kelsey SeptimioFort Mill$229
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.